TITLE

Treatment with pioglitazone induced significant, reversible mitral regurgitation

AUTHOR(S)
Dorkhan, Mozhgan; Dencker, Magnus; Frid, Anders
PUB. DATE
January 2008
SOURCE
Cardiovascular Diabetology;2008, Vol. 7, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
ACCESSION #
55716370

 

Related Articles

  • A differentiated morphological parameter-coding system to describe the suitability of mitral valve stenoses intended for percutaneous valvotomy. Bogunovic, Nikola; Horstkotte, Dieter; Scholtz, Werner; Faber, Lothar; Bogunovic, Lukas; Buuren, Frank // Heart & Vessels;Sep2015, Vol. 30 Issue 5, p632 

    Percutaneous balloon-mitral-valvotomy (PBMV) is an alternative to surgery in selected patients with mitral valve (MV) stenosis (MS). Applying echocardiography, suitability for PBMV is assessed by detailed morphological description. Echo-scores alone are suboptimal to describe MV morphology,...

  • Double Orifice Mitral Valve With Flail Leaflet: a Transoesophageal Echocardiographic Examination. Purnode, P.; Rombaut, E.; Gerard, M.; Alkhori, M.; Marchandise, B. // European Journal of Echocardiography;2000, Vol. 1 Issue 2, p144 

    We describe a case of double orifice mitral valve and a flail leaflet in a 54-year-old man.This rare congenital abnormality was disclosed through the discovery of a murmur. The transoesophageal approach clearly showed two approximately equal orifices with multiple papillary muscles. Colour...

  • Moderated Posters sessionNew insights into risk stratification in valvular heart disease - Part B.  // European Heart Journal - Cardiovascular Imaging;Dec2013, Vol. 14 Issue suppl_2, pii18 

    The article presents abstracts of research papers on risk stratification in valvular heart disease including "Left Atrial Strain for Prognosis Prediction in Patients With Moderate Mitral Valve Regurgitation," "Moderate to Severe Tricuspid Regurgitation Is an Independent Predictor for Early...

  • Mitral regurgitation secondary to mitral anterior leaflet rupture after mitral valvuloplasty. Demirkol, Sait; Ünlü, Murat; Balta, Şevket; İyisoy, Atila // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Dec2012, Vol. 12 Issue 8, Special section pE-40 

    The article presents a case study of a 32-year-old female patient who was suffering from mitral regurgitation.

  • First patients enrolled in Evalve's post-market study.  // Medical Device Daily;4/10/2009, Vol. 13 Issue 68, p1 

    The article reports on the enrollment of the first subject in the ACCESS-Europe study, a post-market observational study of Evalve's MitraClip for the percutaneous repair of cardiac valves. The MitraClip system is noted to be the first commercially available treatment in Europe and the U.S. for...

  • Evalve reports 1st Austrian implants of Mitracilp.  // Medical Device Daily;9/14/2009, Vol. 13 Issue 176, p7 

    The article reports on the treatment of the first group of patients with the MitraClip system from Evalve at the Elisabethinen Krankenhaus in Linz, Austria. According to Evalve, the MitraClip system is the only medical device commercially available in the European Union (EU) which offers a...

  • Mitral Transcatheter Technologies. Maisano, Francesco; Buzzatti, Nicola; Taramasso, Maurizio; Alfieri, Ottavio // Rambam Maimonides Medical Journal;Jul2013, Vol. 4 Issue 3, p1 

    Mitral valve regurgitation (MR) is often diagnosed in patients with heart failure and is associated with worsening of symptoms and reduced survival. While surgery remains the gold standard treatment in low-risk patients with degenerative MR, in high-risk patients and in those with functional MR,...

  • Percutaneous Mitral Valve Repair: A Status Report. Kar, Saibal; Whisenant, Brian; Kapadia, Samir; Lim, Scott // Medical Roundtable: Cardiovascular Edition;Spring2012, Vol. 3 Issue 2, p110 

    The article presents a roundtable discussion on mitral valve repair held on December 7, 2011 featuring several doctors including Brian Whisenant, Samir Kapadia, and Scott Lim. Kapadia discusses limitations of surgery for treating mitral regurgitation (MR) in patients with functional MR. Lim says...

  • Percutaneous and Surgical Treatment of Mitral Valve Regurgitation. Seeburger, Joerg; Katus, Hugo A.; Pleger, Sven T.; Krumsdorf, Ulrike; Mohr, Friedrich-Wilhelm; Bekeredjian, Raffi // Deutsches Aerzteblatt International;12/2/2011, Vol. 108 Issue 48, preceding p816 

    Background: Mitral valve regurgitation is the second most common clinically relevant valvular heart disease in adults, with an incidence of about 2% to 3% per year. Surgical mitral valve repair is the treatment of choice. Recent years have seen major advances in minimally invasive mitral valve...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics